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Objectives: The ongoing ASCEND trial of natalizumab utilizes a novel composite 
endpoint, comprised of the Expanded Disability Status Scale (EDSS), Timed 25-Foot 
Walk (T25FW) and 9-Hole Peg Test (9HPT) to assess disability progression in patients 
with secondary-progressive multiple sclerosis (SPMS), due to the limited ability of 
EDSS alone to assess disability progression in this patient population. Given that 
the ASCEND data are not available, data from the IMPACT study was used to assess 
the cost-effectiveness of SPMS treatments in an economic model capturing the 
interrelated changes of these measures for individual patients. This study presents 
the model concept and assesses its external predictability. MethOds: A discrete 
event simulation was developed to predict times to disability progressions on EDSS, 
T25FW, and 9HPTand the occurrence of relapses over time, using four parametric 
(Weibull) functions, each adjusted by a Cox model to ensure that each event time 
was estimated based on patients’ baseline and time-varying factors. Each disability 
scale’s value is updated as events occur. Data from the IMPACT study (n= 436, fol-
lowed for 2 years) was extrapolated for longer term. Published data on EDSS from the 
University of British Columbia (UBC) MS database were used for long-term external 
validations. Results: The model closely replicated all four endpoints as observed 
in the IMPACT study at two years. The predicted times for 25% of patients to reach 
EDSS 8 were consistent with those from the UBC data, with 13.4 (model) vs. 14.8 
(UBC) years from EDSS 3.5–4.5, and 8.7 vs. 8.6 years from EDSS 6.0. The distributions 
of T25FW and 9HPT by EDSS level predicted at 10 years were consistent with those 
observed from the IMPACT study. cOnclusiOns: This SPMS model reliably pre-
dicts short- and long-term disability levels, and can serve as the basis for economic 
evaluations of treatments for SPMS.
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Objectives: In a budget impact analysis (BIA), the population is supposed to 
include all patients eligible for the new intervention during the time span of deci-
sion: new incident cases and patients leaving due to death, cure, migration or other 
reasons, must be captured. Additionally, temporal changes in the actual number of 
individuals receiving the intervention must be quantified. While most of the guide-
lines for BIA emphasize this population dynamics aspect, recommendations on how 
to technically implement it are lacking. We introduce a method for implementing 
population dynamics in a chronic disease with multiple disease subtypes using 
object-oriented programming (OOP), and demonstrate its application in model-
ling health and budget impact of a treatment strategy for ankylosing spondylitis 
(AS). MethOds: A generic hierarchical patient class structure was developed to 
systematically organize the prevalent population and incident cohorts of patients 
with different disease subtypes. Using the concepts of inheritance and polymor-
phism in OOP, we formulated algorithms to efficiently compute health measures 
and resource utilization of individual patients in different classes, and to perform 
probabilistic sensitivity analysis. In the case study, a dynamic population model was 
developed to predict the burden of AS in the Dutch society over a 20-year period from 
January 1, 2015 onwards when a sequential treatment strategy including tumour 
necrosis factor antagonists was applied. Data for model parameterization were 
obtained from the Outcomes Assessment of AS International Study (OASIS) and 
literature. Results: The case study demonstrated that our dynamic population 
modelling method offers an efficient approach to quantify annual as well as total 
health and costs for different decision time spans. Annual direct costs incurred 
by the AS patients in the Dutch Society would range from 471 to 496 million Euros 
between 2015-2035. cOnclusiOns: Our method for implementation of population 
dynamics is efficient and generic, so it can be applied to other chronic diseases.
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Objectives: To evaluate the economic impact of a recently approved therapy, 
delayed-release dimethylfumarate (DMF; also known as gastro-resistant DMF), on 
the overall management costs of relapsing-remitting multiple sclerosis (RRMS) in 
Italy. MethOds: A budget impact model, adopting the perspective of the Italian 
National Healthcare Service (NHS), was used to compare healthcare costs of two 
different treatment scenarios: a) base-case, in which DMF is not reimbursed/funded 
by the NHS, vs. b) reimbursement-case, in which DMF is reimbursed and funded by 
the NHS. Healthcare costs sustained by the Italian NHS to manage the RRMS popu-
lation (drug treatment, administration, therapy and disease monitoring, relapse 
management, treatment-related adverse events) have been calculated over 3 years 
and compared for the two scenarios. Impact of relapses for the disease modify-
ing therapies (DMTs) included in the analysis was estimated using results from 
published literature. RRMS population treated with DMTs was estimated using 
Italian prevalence and incidence data. According to these estimates, the number 
of treated patients amounted to 35,100 at Year 1, 36,800 at Year 2, and 38,700 at Year 
3. Results: According to current price and reimbursement conditions established 
by the Italian NHS, it was estimated that the introduction of DMF (reimbursement-
case) would determine a decrease of the budget impact, if compared with the 
base-case (non-reimbursement case). Over three years, the budget impact would 
be € 1,388,640,000 in the base-case and € 1,359,800,000 in the reimbursement-case 
(-€ 28,840,000; -2.1% relative budget variation). The main drivers for cost-saving were 
pharmacological treatment costs and reduced burden of relapses (corresponding 
to about 1,500 avoided relapses). cOnclusiOns: At the current reimbursement 
increased risk of secondhand smoking on morbidity and mortality. The impact of 
secondhand smoking was included in a previously published Markov model called the 
BENESCO model to estimate the economic burden in Korea. Transition probabilities 
and costs were acquired from Korean public data. The time horizon was lifetime and 
assumed 5% discount rate for costs. The estimated cost was compared with published 
estimates to establish external validity of the model. Results: 13.7% of women (≥ 
19 years old) and 30.7% of children (13-18 years old) from general population were 
exposed to secondhand smoke in household. Relative risks of secondhand smoking 
related diseases were lung cancer 1.9(95% CI 1.0-3.5), coronary heart disease 1.27(95% 
CI: 1.19-1.36), stroke 1.25(95% CI: 1.12-1.38) in women married for smoking husbands. 
The odd of Asthma onset was 1.32 times higher in children whose father smokes. The 
estimated costs were increased by 10 to 50%, compared with the model without the 
impact of secondhand smoking. cOnclusiOns: Cigarette smoking and exposure 
to secondhand smoke is associated with significant economic burden. Policymakers 
should be advised that tobacco control should be aimed not just smokers, but those 
who are vulnerable to secondhand smoking, especially women and children lived 
with smokers.
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Objectives: UKPDS 82 provided updated and new event equations for use in type 
2 diabetes mellitus (T2DM) that include new risk factor (RF) predictors. These new 
RFs do not routinely get reported in clinical studies; consequently, the objective 
of this study research was to report plausible baseline RF values and their time-
dependent trajectories and quantify their impact upon predicted complication 
rates. MethOds: Availability of baseline and time-dependent RF data was assessed 
using a pragmatic literature review. Univariate sensitivity analysis of the UKPDS 82 
equations (over a 40-year horizon ) was undertaken to assess the impact of low-
density lipoprotein [LDL]; microalbuminuria (MA); heart rate (HR); white blood cell 
count (WBC): haemoglobin (Hb) and estimated glomerular filtration rate (eGFR) on 
predicted diabetes complications per 1,000 patients, using UKPDS baseline values 
(varied within the 95% central range). Results: The review identified 32 studies 
reporting baseline RF values typically consistent with UKPDS (review versus UKPDS): 
LDL (2.6-3.8 versus 3.49mmol/l); MA (11-45% versus 6.5%); HR (67-72 versus 72bpm); 
WBC (5.7-7.9 versus 6.6x106/ml); Hb (12.4-14 versus 14.5g/dl); the exception was 
eGFR where baseline values (33-101 versus 77.5ml/min/1.73m2) and decline (0.3-
5.2ml/min/1.73m2/year) varied widely. Utilising UKPDS 82 baseline values resulted 
in 877 macrovascular and 133 microvascular events predicted with 691 to 1,181 and 
116 to 182, respectively, predicted in sensitivity analyses; drivers of risk were LDL 
and eGFR. Varying eGFR decline between 0.3 to 5.2ml/min/1.73m2/year resulted 
in annual event rates for end stage renal disease (ESRD) between 0.021 to 1.251%; 
holding eGFR constant over time resulted in ESRD annual event rate of 0.020%, 
significantly lower than observed in UKPDS (0.13%). cOnclusiOns: Appropriate 
specification of RF is important in diabetes modelling. This study suggests that 
the UKPDS profile is generally consistent with other identified T2DM populations. 
Modelling a decline in eGFR improved the predictive accuracy of ESRD incidence.
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Objectives: Erlotinib, a tyrosine-kinase inhibitor, has been recommended for use in 
non-small cell lung cancer patients harbouring an EGFR mutation. The present study 
is retrospective in nature; using published clinical trial data for erlotinib, it demon-
strates how an analysis of Phase II data could be used to identify what data Phase III 
studies should focus on collecting. MethOds: Phase II data were identified through 
a targeted literature search and used to determine the cost-effectiveness of erlotinib, 
utilising a simple Markov model framework. Data from the literature were mapped 
to model inputs using statistical data analysis methods. Value of Information (VOI) 
analysis tools, such as Expected Value of Perfect Information (EVPI) and Expected 
Value of Partial Perfect Information (EVPPI) were used to identify those uncertain 
parameters having research value in a prospective Phase III program. These findings 
helped to optimise the design of a hypothetical Phase III trial for erlotinib that could 
collect data that is most relevant for reimbursement decision-making. Results: 
At a cost-effectiveness threshold of £30,000 per quality-adjusted life year (QALY) 
gained, the population EVPI was £3,269,358, indicating that further research is valu-
able. The EVPPI identified the log hazards of erlotinib (intervention) and gefitinib 
(comparator) for progression-free survival and overall survival as the parameters for 
which uncertainty was the most valuable. The value of the uncertainty associated 
with other parameters, such as utilities and costs, was much lower. Hence, subse-
quent studies should focus on providing further information on efficacy parameters 
rather than on utilities and costs. cOnclusiOns: Undertaking VOI analysis on data 
collected at Phase II can help ensure that Phase III trials are designed efficiently, in 
turn ensuring that uncertainty in future decision-making is minimised. This model 
demonstrated the VOI from a public policy perspective. This could be extended to 
other perspectives to ensure greater relevance in different settings.
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